Sign in
Taking peopleNo phase

Mitral Valve Prolapse Arrhythmic Risk

Key facts

Who runs it
Oslo University Hospital
Where
Norway1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
500 people, planned
Started
7 Aug 2026
Expected to end
Sept 2035
Type of study
Observational
Treatments tested
  • Risk prediction model
Record updated
29 September 2026

Who can take part

Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • MVP according to the ESC definition AND
  • Arrhythmic burden of:
  • A total PVC burden ≥ 0,5 % per day OR
  • Documentation of NSVT on any modality OR
  • More severe ventricular arrhythmias (sustained ventricular tachycardia, ventricular fibrillation, aborted cardiac arrest) that occurred >1 month after the beginning of follow up; AND
  • Follow up >6 months

Who cannot take part

  • VT/VF as the initial presentation without prior cardiac evaluation (ECG, echo, Holter)
  • History of myocardial infarction
  • Obstructive coronary diseases - ≥50 % stenosis that was not treated
  • History of coronary artery bypass surgery
  • Significant valve disease other than MVP - rheumatic heart disease, severe aortic stenosis
  • Carrier of disease causing mutation known to be associated with arrhythmia even when phenotype is negative (e.g. Lamin A/C)
  • Sustained ventricular arrhythmia clearly caused by a reversable cause
  • Primary inherited arrhythmia - Brugada syndrome, short QT, long QT, CPVT
  • LGE suggestive of probable myocarditis as the etiology

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Mitral valve prolapse (MVP) is common with a 2-3 % prevalence in the general association and generally associated with a favorable prognosis. However, a subgroup of MVP patients, known as arrhythmic mitral valve prolapse (AMVP) has an increased burden of severe ventricular arrhythmias and risk of sudden cardiac death. Identifying high risk patients who may benefit of potential implantable cardioverter-defibrillator (ICD) implantation is therefore critically important. Risk stratification in AMVP is still challenging, and the ability to estimate arrhythmic risk at the individual level is limited.

The group in the trial

  • Patients with Mitral Valve Prolapse and Ventricular Arrhythmias

    Patients with mitral valve prolapse and ventricular arrhythmias will be included in the study cohort. Clinical, echocardiographic, arrhythmic and other cardiac imaging variables will be evaluated in relation to the occurence of life-threatening ventricular arrhythmias. No study-specific intervention is performed.

    Treatment: Risk prediction model

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Development and Validation of Risk Prediction Model for Severe Ventricular Arrhythmias in Patients With Mitral Valve Prolapse
Record updated
29 September 2026